BIOTECH CATALYST AI SCANNER — August WK1

The top of this week's list is a wreckage report. Karyopharm ($KPTI) takes the #1 slot down 80% on the month after a Phase 3 miss on July 30. Capricor ($CAPR) sits at #5 down 83% after an FDA advisory committee voted 9–3 against its drug on July 29. Ultragenyx ($RARE) is on the watchlist at an RSI of 11. Three of the four worst charts in this report were made in the last five trading days, and the scanner ranked them anyway — because its screen rewards the gap between a beaten-down price and a catalyst that hasn't happened yet. That is a legitimate way to find dislocation, and it is also exactly how you end up holding something that deserved to fall. Every one of those entries below carries the specific reason it fell, up front.

August is where this year's regulatory calendar bunches up. Capricor's PDUFA lands August 22, Ultragenyx's the day after on August 23. The ESC Congress in late August absorbs three names at once — Tenax ($TENX) presents Phase 3 data on the 29th, Arrowhead ($ARWR) its 12-month detail on the 30th, and Ionis ($IONS) brings both an early siRNA readout and the post-mortem on a Phase 3 that already failed. Everything else in the "Aug 2026 (Est.)" bucket is a company-guided window, not a date on a calendar. Read the granularity accordingly.

One housekeeping note: as flagged in late July, this weekly newsletter winds down at the end of August. Four issues remain, this one included. Deep-dive pieces continue after that.

What We're Tracking:

Trading Below Gross Cash: CAPR ($223M cap / $279M cash), KPTI ($43M cap / $91M cash — but see the debt note in its entry), TRDA (roughly at cash)
Genuine Cash Pressure: NTHI (~$0.4M on hand, funded into September 2026 via PIPE), CHRS
Post-Setback, Still Listed: KPTI (Phase 3 miss Jul 30), CAPR (AdCom 9–3 against Jul 29), IONS (Phase 3 miss Jul 9)
Deeply Oversold (RSI < 20): CAPR (8), KPTI (10), RARE (11)
Multi-Catalyst (90 days): IONS, NTHI, EYPT, ARWR
Corrected False "Cash Crunch" Flags: EYPT, PYXS, TRDA, RARE

FEATURED

#1. KPTI — Karyopharm Therapeutics Inc.

THE CATALYST
Event: Selinexor (XPORT-MF-034, SENTRY) — sNDA submission seeking accelerated approval in JAK-inhibitor-naïve myelofibrosis
Date: Aug 2026 (Est.)
FDA Status: FTD
BSI: 7.92/10

Karyopharm's Phase 3 endometrial cancer trial missed its primary endpoint on July 30 and the stock lost roughly two-thirds of its value in a session — but the failed program is not the one this month's filing rests on. The company is built around selinexor (Xpovio), an XPO1 inhibitor already approved and selling in multiple myeloma. Management is cutting endometrial spend and concentrating on myelofibrosis and myeloma. No major partner is disclosed on the myelofibrosis program.

A note on the balance sheet, since the screen's framing is incomplete. Two things are true at once here and both belong in the file. Karyopharm is genuinely commercial — $35.1M of revenue in Q1 2026, $29.2M of it U.S. Xpovio, against reaffirmed full-year guidance of $130–150M — and its $43M market cap does sit below roughly $91M of cash. That is a real observation, and it is why our screen tagged the name "Negative EV." But the screen only counts cash. The Q1 10-Q shows $397M of total liabilities against $131M of total assets, a stockholders' deficit of $265.6M, a senior secured term loan, 9% convertible notes due 2028 and 2029, a $72.3M deferred royalty obligation — and an explicit going-concern warning. Net of debt, enterprise value is strongly positive, not negative. The cash-above-market-cap optic is arithmetically correct and the conclusion usually drawn from it is not.

📈 The Setup: Myelofibrosis (a bone-marrow cancer that scars the marrow and enlarges the spleen) is owned in the front line by Incyte's ruxolitinib (Jakafi), with fedratinib, pacritinib, and momelotinib picking up narrower subgroups. Selinexor works by a different route — it blocks XPO1, the export protein tumour cells use to shuttle tumour-suppressor proteins out of the nucleus where they can't function. In the Phase 3 SENTRY trial (N=353, randomised 2:1), adding it to ruxolitinib produced SVR35 — a 35% or greater reduction in spleen volume at week 24 — in 49.8% of patients versus 28.0% on ruxolitinib alone (p<0.0001), with responses appearing by week 12 and no new safety signals. The co-primary symptom-score endpoint was missed. If approved, this would be the first combination regimen in JAK-naïve disease. The August filing is a submission, not a decision — the FDA response is a 2027 event.

✅ The Edge: A near-doubling of spleen response over the standard of care, with a nominal overall-survival hazard ratio of 0.43 at roughly 12 months. No approved agent has beaten ruxolitinib monotherapy on that endpoint in the front line, and Fast Track is already in hand.
⚠️ The Risk: SENTRY cleared one co-primary and missed the other. The FDA can reasonably demand the symptom-score result or mature survival data before granting accelerated approval — and a company with a going-concern flag and 2028 convertible maturities has limited capacity to fund the wait.

#2. LGVN — Longeveron Inc.

THE CATALYST
Event: Laromestrocel (lomecel-B, ELPIS II) — Phase 2b topline data in hypoplastic left heart syndrome
Date: Aug 2026 (Est.)
FDA Status: FTD, ODD
BSI: 7.58/10

An independent data monitoring committee reviewed the unblinded results from all 40 patients on May 11 and cleared the trial to finish unchanged — an outside read on the data that no public investor can get. Longeveron develops allogeneic mesenchymal stem-cell therapies for rare paediatric and ageing-related conditions, with Alzheimer's and frailty programs behind the lead asset. A $15M first tranche of a $30M private placement closed in March, funding the company past this readout, and it has shifted to a leaner, asset-light operating model while pursuing licensing partners.

📈 The Setup: Hypoplastic left heart syndrome is a birth defect in which the left side of the heart never properly forms. Treatment is three staged open-heart operations — Norwood, Glenn, Fontan — that leave the right ventricle doing the work of two, with high rates of failure and transplant. There is no drug. Laromestrocel is a donor-derived, off-the-shelf mesenchymal stem-cell therapy injected into the heart muscle during the Glenn procedure, working through pro-vascular, anti-inflammatory and tissue-repair signalling rather than by replacing tissue. The ELPIS I Phase 1 (n=10 infants) showed 100% transplant-free survival at five years and a statistically significant improvement in tricuspid regurgitant fraction. ELPIS II reads out this quarter against surgery alone — there is no pharmacological comparator to beat, only the historical surgical record.

✅ The Edge: A DMC that has already seen all 40 patients' unblinded data and waved the trial through, in an indication where no competitor has a cell or regenerative therapy in pivotal development. Fast Track and orphan status are in hand and a BLA is in the stated 2026 plan.
⚠️ The Risk: Forty patients is a thin base for a composite endpoint, and mesenchymal stem-cell therapies have a long track record of encouraging mid-stage signals that vanish in confirmatory work. FDA has not confirmed it accepts the sponsor's composite or its analysis plan.

#3. SLN — Silence Therapeutics Plc

THE CATALYST
Event: Divesiran (SLN124, SANRECO) — Phase 2 topline data in polycythemia vera
Date: Aug 2026 (Est.)
FDA Status: FTD, ODD
BSI: 7.04/10

Divesiran is the asset Silence kept. After years of building value through partnered siRNA programs — the AstraZeneca collaboration across cardiovascular, renal, metabolic and respiratory targets still runs — this is the wholly-owned lead going into a readout the company controls end to end. The parent is UK-domiciled and Nasdaq-listed. An EHA 2026 data update in June kept attention on the polycythemia vera program ahead of this month's topline.

📈 The Setup: Polycythemia vera is a blood cancer that overproduces red cells, and the standard management is still physically draining blood — therapeutic phlebotomy — supported by hydroxyurea or ropeginterferon (Besremi), with ruxolitinib for hydroxyurea-intolerant patients. Divesiran attacks the supply chain instead. It is a GalNAc-conjugated siRNA (a small RNA that silences a specific gene, chemically tagged to home to the liver) targeting TMPRSS6, which raises hepcidin, the hormone that restricts how much iron reaches the marrow. Starve the iron, throttle the overproduction. Phase 1 (n=21) drove mean haematocrit to ≤45% across all doses with phlebotomies essentially eliminated and the effect persisting after dosing stopped. The Phase 2 is fully enrolled and tests every-6-week and every-12-week schedules. This is a genuine topline efficacy readout.

✅ The Edge: Takeda and Protagonist's rusfertide works the same hepcidin axis but needs weekly injections. The Q12W arm is testing a dosing interval no competitor is positioned to match, in a chronic disease where adherence is the practical constraint.
⚠️ The Risk: No siRNA or hepcidin-modulating agent has been approved in polycythemia vera, so there is no precedent for what regulatory package the FDA will want. Variable background cytoreductive use across a small trial could also blur the separation the thesis rests on.

#4. AVBP — ArriVent BioPharma Inc.

THE CATALYST
Event: Furmonertinib (FURVENT) — Phase 3 topline data in first-line EGFR exon 20 insertion NSCLC
Date: Aug 2026 (Est.)
FDA Status: BTD
BSI: 6.92/10

ArriVent is an in-licensing vehicle rather than a discovery platform, and essentially all of its value sits in one Phase 3 that reads out this month. The lead asset came from a 2021 exclusive licence with Shanghai Allist covering development outside Greater China; a January 2025 deal with Lepu Biopharma added an antibody-drug conjugate now in Phase 1. An ATM equity program raised $54.7M net in Q1, pushing funding into late 2027 — so this readout is not happening with a financing gun to the head.

📈 The Setup: EGFR exon 20 insertion lung cancer is a mutation subtype that most EGFR pills structurally cannot reach, and J&J's amivantamab plus chemotherapy took the first line on the strength of the PAPILLON trial — an infused bispecific antibody with a demanding tolerability profile. Furmonertinib is an oral, brain-penetrant third-generation EGFR tyrosine kinase inhibitor (a pill that blocks the mutated growth signal) already approved in China for classical EGFR mutations. In the FAVOUR Phase 1b, treatment-naïve patients (n=28) hit a 79% confirmed response rate, and the FDA's Breakthrough designation was granted specifically on that durability and its central-nervous-system activity. FURVENT randomises 398 patients across two doses versus platinum-pemetrexed chemotherapy, with progression-free survival by blinded independent review as the primary endpoint and CNS-specific secondary endpoints in patients with brain metastases.

✅ The Edge: It is the only late-stage oral candidate reaching pivotal first-line data in this mutation. Sunvozertinib holds accelerated approval only post-platinum and zipalertinib is still in Phase 3 — an oral drug that controls brain metastases and spares patients the infusion chair is a real wedge against an entrenched IV regimen.
⚠️ The Risk: The trial enrols across the U.S., Europe, Japan and China, and the prior efficacy data was China-centric. Population and background-care differences are exactly what turns a 79% single-arm response rate into a disappointing randomised PFS curve.

#5. CAPR — Capricor Therapeutics Inc.

THE CATALYST
Event: Deramiocel (CAP-1002, HOPE-3) — PDUFA regulatory decision in Duchenne muscular dystrophy
Date: Aug 22, 2026
FDA Status: ODD
BSI: 6.81/10

On July 29 an FDA advisory committee voted 9–3 that HOPE-3 did not provide sufficient evidence of efficacy, and the PDUFA date is 24 days later. This is the second regulatory blow to the program — a Complete Response Letter in July 2025 was addressed by resubmission, and that resubmission is what now sits in front of the agency. Capricor works in cell and exosome therapeutics for rare disease and holds a U.S. and Japan commercialisation agreement with Nippon Shinyaku/NS Pharma, though it filed litigation over the distribution terms in May 2026. The stock trades below its cash.

📈 The Setup: Duchenne muscular dystrophy has approved therapies — eteplirsen, givinostat, Sarepta's gene therapy Elevidys — and not one of them carries a label for the cardiomyopathy that ultimately kills most patients. Deramiocel is an allogeneic cardiosphere-derived cell therapy: the infused cells survive only briefly but secrete exosomes (small vesicles carrying signalling cargo) that push macrophages toward an anti-inflammatory, anti-fibrotic state. In HOPE-3 (n=106, largely non-ambulatory patients), it met its primary endpoint with a 54% slowing of upper-limb functional decline on the PUL 2.0 scale at 12 months (p=0.03), alongside preserved left-ventricular ejection fraction. The committee's 9–3 vote went specifically to whether that package proves cardiomyopathy benefit. The market has priced a rejection; the question is only whether the FDA departs from a non-binding vote.

✅ The Edge: A statistically significant functional result plus cardiac preservation in non-ambulatory patients, in a complication no approved DMD therapy addresses. Cash exceeds market capitalisation and funds operations into late 2027 regardless of the August outcome — the company survives a CRL.
⚠️ The Risk: Advisory committees are advisory, but the FDA follows them most of the time, and this one landed on the central efficacy question after a prior CRL on the same asset. A second rejection would force new trials while the NS Pharma distribution dispute is still unresolved in court.

#6. TENX — Tenax Therapeutics Inc.

THE CATALYST
Event: TNX-103 (oral levosimendan, LEVEL) — Phase 3 topline data in PH-HFpEF
Date: Aug 29, 2026
BSI: 6.75/10

A blinded sample-size re-estimation completed before database lock confirmed the trial is powered above 90% for its primary endpoint — a de-risking step most single-asset companies never get to announce. Tenax holds global rights to oral levosimendan and is running two registrational Phase 3 trials, LEVEL and LEVEL-2. Warrant exercises in Q2 brought in $13.4M on top of prior private placements with RTW Investments, funding the company through Q2 2028. No competitor approval or pipeline setback has changed the landscape into this readout.

📈 The Setup: Pulmonary hypertension with preserved ejection fraction has no approved therapy at all. Physicians borrow drugs developed for pulmonary arterial hypertension — endothelin receptor antagonists like macitentan, prostacyclin analogues — with no evidence base in this population. TNX-103 is an oral formulation of levosimendan, an inodilator that sensitises cardiac troponin C to calcium and opens ATP-sensitive potassium channels, improving contraction while relaxing the vasculature. The Phase 2 HELP trial with the IV form produced meaningful gains in six-minute walk distance. LEVEL enrolled over 230 patients and completed enrolment in March, testing a 25-metre improvement in walk distance at 12 weeks against placebo. Data goes straight to the ESC Congress stage on August 29. Clean bar, empty field, single dataset.

✅ The Edge: First-mover into an indication with zero approved options and an FDA already aligned on six-minute walk distance as the primary endpoint — no cardiovascular outcomes trial demanded. The oral formulation removes the infusion burden that limits the IV drug.
⚠️ The Risk: Everything rests on one 12-week functional endpoint with no backup asset carrying comparable momentum. Twelve weeks also says nothing about durability, and a functional win without durability is a hard sell to payers managing a heavily comorbid population.

#7. ZBIO — Zenas BioPharma Inc.

THE CATALYST
Event: Obexelimab (SunStone) — Phase 2 topline data in systemic lupus erythematosus
Date: Aug 2026 (Est.)
BSI: 6.60/10

Zenas already has its win — positive Phase 3 INDIGO results in IgG4-related disease led to a BLA submission in Q2 — and this lupus readout is the test of whether the same antibody travels. The company is focused on autoimmune disease and has financed aggressively: roughly $419M gross from Q1 equity and convertible offerings plus an ATM, a $250M Pharmakon debt facility closed in March, and a Royalty Pharma agreement worth up to $300M tied to obexelimab milestones. Funding reaches into 2029 on management's assumptions.

📈 The Setup: Lupus is defended by two established biologics — GSK's belimumab (Benlysta) and AstraZeneca's anifrolumab (Saphnelo) — and the field is littered with B-cell agents that could not clear them. Obexelimab is a humanised anti-CD19 antibody engineered to also engage FcγRIIb, an inhibitory receptor that switches B cells off rather than destroying them, so it suppresses without full depletion. The honest history matters here: an earlier Phase 2 in lupus (n=104) missed its primary endpoint, 42% versus 29% on placebo (p=0.183), while showing a significant prolongation of time to loss of improvement (HR 0.53) and roughly 50% B-cell reduction. SunStone is the first randomised look at the same mechanism in the same disease since. The IgG4-RD Phase 3 proves the antibody works somewhere; it does not prove it works here.

✅ The Edge: Dual CD19/FcγRIIb engagement is a genuinely different mechanism from BAFF or interferon blockade, and a Phase 3 win in IgG4-related disease already demonstrated the molecule can hit a hard endpoint. The balance sheet removes financing risk from the equation entirely.
⚠️ The Risk: This mechanism has already failed a primary endpoint in this indication once. A time-to-event signal in a missed trial is a hypothesis, and repeating the study is how hypotheses usually get disproven.

#8. BEAM — Beam Therapeutics Inc.

THE CATALYST
Event: BEAM-302 — Phase 1/2 data presentation at ERS in severe alpha-1 antitrypsin deficiency
Date: Sep 08, 2026
FDA Status: RMAT
BSI: 6.58/10

Beam has $1.2B in the bank, funding into mid-2029, and an FDA already aligned on an accelerated approval pathway using a biomarker endpoint — and the stock is down 27% on the month. The company develops precision genetic medicines using base editing, a technique that rewrites a single DNA letter rather than cutting the strand, focused on liver-targeted genetic disease and haematology. No co-development partner is disclosed on BEAM-302. A roughly 50-patient pivotal expansion cohort is set to open in the second half of this year.

📈 The Setup: Alpha-1 antitrypsin deficiency is caused by a single mutation, Z, that makes a misfolded protein which both fails to protect the lungs and accumulates toxically in the liver. Approved augmentation therapies like Prolastin-C infuse replacement protein weekly, treat only the lung half of the disease, and do nothing about the liver. BEAM-302 corrects the mutation itself, using a lipid nanoparticle to deliver a base editor that converts the Z variant back to wild-type. In the BEACON trial, a single 60 mg dose produced steady-state total AAT of 16.1 µM with an 84% mean reduction in mutant protein sustained across 5–12 months of follow-up — above the roughly 11 µM threshold that defines functional protection. Wave Life Sciences and Korro Bio are pursuing the same correction by RNA editing but sit behind in Phase 1/2. ERS in September is a conference presentation of maturing data, not a pivotal event.

✅ The Edge: The most advanced in vivo gene-editing program in this disease, with single-dose durability data that already clears the functional protection threshold and addresses the liver manifestation no augmentation therapy touches. RMAT designation and an agreed biomarker pathway shorten the road considerably.
⚠️ The Risk: Twenty-nine patients dosed is a small safety base for a permanent edit. Liver transaminase signals or immunogenicity to the editor itself in a broader cohort would put the biomarker-based accelerated pathway back under negotiation — and gene-editing programs have historically drawn extra FDA safety requirements at exactly this transition.

#9. IONS — Ionis Pharmaceuticals Inc.

THE CATALYST
Event: ION775 — Phase 1 data presentation at ESC in hypertriglyceridemia
Date: Aug 31, 2026
Additional catalysts: 1 more within 90 days — eplontersen (CARDIO-TTRansform) full Phase 3 results at ESC
BSI: 6.51/10

Read the two ESC presentations separately, because only one of them is a pending question. Eplontersen's Phase 3 in ATTR cardiomyopathy already missed its primary composite endpoint on July 9 — the August presentation is the full dataset and a subgroup post-mortem, not a live binary, and the 37% monthly drawdown is that miss being absorbed. Ionis itself is a different proposition: an RNA-targeted drug developer with Biogen and GSK partnerships, two of its own recent U.S. launches in TRYNGOLZA and DAWNZERA, a June licensing deal with Recordati, and $2.06B on the balance sheet against guidance to cash-flow breakeven in 2028.

📈 The Setup: Severe hypertriglyceridemia is treated with fibrates, icosapent ethyl, and — as of its recent launch — Ionis's own olezarsen, an antisense oligonucleotide that lowers apoC-III with monthly subcutaneous dosing. ION775 targets the identical protein by a different modality: it is Ionis's first clinical-stage siRNA, a small RNA that triggers destruction of the target's messenger RNA rather than blocking it. Early data in volunteers with elevated triglycerides showed durable apoC-III and triglyceride reductions after a single dose, pointing toward twice-yearly administration. That is the entire thesis — a company known for antisense showing it can compete in the modality that displaced it. It is also Phase 1 data in healthy-ish volunteers presented at a cardiology conference, which is a long way from proving anything in patients.

✅ The Edge: A semiannual injection against a monthly one is a real commercial difference in a chronic lipid disorder, and Ionis has already established with the FDA — via olezarsen — that apoC-III reduction is an acceptable basis for approval here. The regulatory precedent is its own.
⚠️ The Risk: ION775's most direct competitor is olezarsen, which Ionis already sells. Even a clean result creates an internal formulary conflict, and healthy-volunteer triglyceride reductions routinely shrink in patients with severe baseline disease and comorbidities.

#10. NTHI — NeOnc Technologies Holdings Inc.

THE CATALYST
Event: NEO100-01 — Phase 2a topline data in recurrent WHO Grade 3/4 IDH1-mutant astrocytoma
Date: Aug 2026 (Est.)
Additional catalysts: 1 more within 90 days — NEO100 Phase 1/2 readout
BSI: 6.32/10

The cash position is the story before the science is: NeOnc reported $138,601 on hand at the end of Q1 and is funded into roughly September 2026 on a PIPE anchored by a $10M commitment from Cinctive Capital plus an undrawn $10M credit line. This is one of the few cash-crunch flags in this report that survived verification. The company works exclusively on intracranial malignancy, runs two Phase 2 CNS programs, received FDA feedback on NEO212 manufacturing in July, and cleared a UAE IND for NEO100. The chairman and CEO bought roughly $300,000 of stock.

📈 The Setup: Recurrent high-grade astrocytoma after failure of standard therapy is close to untreatable — lomustine and bevacizumab are the salvage options and produce radiographic responses below 8%. NEO100 is intranasal perillyl alcohol, a monoterpene that disrupts Ras signalling, delivered through the nose to bypass the blood-brain barrier that stops most drugs reaching the tumour. In the Phase 1 portion (n=24 heavily pretreated patients), 5 patients — 21% — achieved confirmed radiographic responses on contrast-enhanced and perfusion MRI, with a third surviving 18 months or more and no significant systemic toxicity. The Phase 2a cohort of 25 is fully enrolled and reads out against that 21% bar. Nothing about the route of administration has been replicated by any approved or late-stage competitor. Nothing about a 25-patient single-arm trial is confirmatory, either.

✅ The Edge: Self-administered intranasal delivery is a genuinely novel route into the CNS, and a 21% confirmed response rate is roughly triple the salvage-therapy benchmark in a population with essentially no options.
⚠️ The Risk: The FDA has historically required randomised data or rigorous external controls for glioma approvals, and single-arm radiographic response has drawn CRLs in comparable settings. With cash funded only into September, a topline that reads ambiguous rather than clean leaves the company financing from a position of no leverage.

WATCHLIST

#11. EYPT — EyePoint Inc. [Ophthalmology]

Price: $12.25 | Cap: $1.0B | Cash: ~$223M (Mar 31, 2026) | RSI: n/a | Momentum: n/a
DURAVYU (EYP-1901, LUGANO) — Phase 3 topline data in wet age-related macular degeneration (Aug 2026 (Est.))
Additional catalyst: LUCIA Phase 3 topline also expected in 2026
BSI: 6.43/10

The Intel: Our feed flagged EyePoint with a "Cash Crunch" and roughly $111M — both wrong. The company reported over $223M as of March 31 with runway guided into Q4 2027, well past these readouts. DURAVYU is vorolanib — a tyrosine kinase inhibitor that blocks VEGF-driven vessel leakage — delivered from a bioerodible intravitreal insert built on the Durasert platform. The pitch is six-month sustained release against Regeneron's Eylea and Roche's Vabysmo, which patients receive by repeat injection every one to two months. Injection burden is the real unmet need in wet AMD, so durability is the endpoint that matters. Technical indicators were unavailable in this week's feed and are not shown rather than reported at false precision.

#12. PYXS — Pyxis Oncology Inc. [Oncology / ADC]

Price: $2.65 | Cap: $168M | Cash: ~$50M raised July 2 | RSI: 56 | Momentum: +0.8%
Micvotabart pelidotin (MICVO, PYX-201-101) — Phase 1/2 interim data update in solid tumors (Aug 2026 (Est.))
FDA Status: FTD, ODD
BSI: 6.42/10

The Intel: A second false "Cash Crunch" — the feed carried $4.9M and a two-week runway. Pyxis closed a $50M private placement on July 2, led by BVF Partners, with up to $64M more on warrant exercise, extending runway into Q2 2027. MICVO is an antibody-drug conjugate that binds extradomain-A fibronectin in the tumour stroma — the supporting scaffold around a tumour rather than the cancer cell itself — and releases a microtubule-inhibiting payload there. Reported head and neck data was strong: 46% confirmed response as monotherapy, 71% combined with Keytruda. Small numbers, early phase, but a stroma-targeted mechanism is a real point of difference in a crowded ADC field.

#13. PSTV → CNSY — Cerenome Inc. (formerly Plus Therapeutics) [CNS Oncology / Radiotherapeutics]

Price: $3.87 | Cap: $27M | Cash: ~$21M | RSI: 40 | Momentum: -2.8%
REYOBIQ (rhenium Re186 obisbemeda, ReSPECT-LM) — Phase 1 data at the SNO/ASCO CNS Metastases Conference (Aug 13, 2026)
FDA Status: FTD, ODD
BSI: 6.34/10

The Intel: Ticker change today: Plus Therapeutics rebranded as Cerenome and moved to CNSY effective August 3 — our feed still carries the old symbol and a mangled company name. REYOBIQ delivers rhenium-186, a beta-emitting radioisotope, in liposomal nanoparticles injected directly into cerebrospinal fluid to irradiate leptomeningeal metastases (cancer that has spread to the linings of the brain and spinal cord). Median overall survival of roughly 9 months was reported at AANS in May against a grim baseline, and a January Type B meeting had the FDA supporting a randomised design with overall survival as primary. This is a conference presentation of Phase 1 data, not the pivotal event.

#14. TRDA — Entrada Therapeutics Inc. [Neuromuscular / Oligonucleotides]

Price: $6.79 | Cap: $264M | Cash: ~$255M (Mar 31, 2026) | RSI: 53 | Momentum: -12.0%
ENTR-601-45 (ELEVATE-45-201) — Phase 1/2 initial data in Duchenne muscular dystrophy (Aug 2026 (Est.))
BSI: 6.29/10

The Intel: Third false "Cash Crunch": the feed showed $18.5M and six weeks of runway. Entrada reported $254.9M at March 31 with runway into Q3 2027 — the company trades at roughly its cash balance, which is close to the opposite of the flagged condition. ENTR-601-45 uses exon skipping, an oligonucleotide that instructs cells to bypass a faulty section of the dystrophin gene, paired with Entrada's endosomal escape vehicle to improve uptake into muscle. Delivery has always been the ceiling on exon-skipping efficacy against Sarepta's approved agents, so this early look is about whether the platform actually raises dystrophin more than the incumbents. Cohort 2 escalated to 10 mg/kg on DMC recommendation in June. First-in-patient data with thin prior evidence — treat it as a delivery-platform signal.

#15. CHRS — Coherus Oncology Inc. [Oncology / Immunotherapy]

Price: $1.41 | Cap: $217M | Cash: ~$167M (Mar 31, 2026) | RSI: 43 | Momentum: -2.8%
Casdozokitug + toripalimab + bevacizumab — Phase 2 data in unresectable hepatocellular carcinoma (Aug 2026 (Est.))
BSI: 6.20/10

The Intel: Cash correction here too, though the pressure is directionally real: the feed carried $87M; Coherus reported $167.0M at March 31 after a $53.65M equity raise. At the current burn that is roughly two to three quarters, so this readout does arrive with financing consequences. Casdozokitug is an IL-27 inhibitor — it blocks an immunosuppressive cytokine tumours use to switch off T cells — combined with a PD-1 inhibitor and an anti-VEGF antibody. A 17.2% complete response rate was previously reported with an atezolizumab-based backbone, which is a genuinely striking number in liver cancer. The obstacle is commercial rather than scientific: Roche's atezolizumab-bevacizumab and AstraZeneca's Imfinzi-tremelimumab own first-line HCC, and a triplet must beat them on benefit and tolerability.

#16. RARE — Ultragenyx Pharmaceutical Inc. [Rare Disease / Gene Therapy]

Price: $24.91 | Cap: $2.5B | Cash: ~$534M (Mar 31, 2026) | RSI: 11 | Momentum: -25.6%
DTX401 (pariglasgene brecaparvovec) — PDUFA regulatory decision in Glycogen Storage Disease Type Ia (Aug 23, 2026)
BSI: 5.94/10

The Intel: Fourth false "Cash Crunch" — the feed showed $139M and a two-month runway against an actual $534M at March 31. Q2 results land August 4, the day after publication, so this figure updates immediately. DTX401 delivers a working G6PC gene into liver cells via an adeno-associated virus vector, restoring the missing enzyme that lets patients break down stored glycogen and avoid life-threatening hypoglycaemia. An RSI of 11 into a PDUFA is an unusual combination — the drawdown reflects broader pipeline and burn concerns rather than anything specific to this filing. One caution from our own archive: this company's programs have previously been conflated in catalyst feeds, and DTX401 is distinct from UX111, which carries its own separate regulatory history. Verify which asset any headline refers to.

#17. ARWR — Arrowhead Pharmaceuticals Inc. [Cardiometabolic / RNAi]

Price: $84.65 | Cap: $11.9B | Cash: ~$1.71B | RSI: 66 | Momentum: +0.8%
Plozasiran (SHASTA-3) — Phase 3 detailed 12-month results at ESC (Aug 30, 2026)
Additional catalyst: SHASTA-4 detailed results, same presentation
BSI: 5.82/10

The Intel: The lowest-drama entry in the report, and the score understates it — both Phase 3 trials already met their primary endpoints, announced July 22. August 30 is the detail: 12-month durability, safety, and the depth of triglyceride lowering that determines label and positioning. Plozasiran uses RNA interference to silence apoC-III, clearing triglycerides with quarterly dosing. The direct comparison is Ionis's olezarsen at #9 — monthly antisense versus quarterly RNAi against the same target, one of the cleaner head-to-head modality contests in cardiometabolic medicine. With $1.71B in cash and the binary already resolved favourably, this is a positioning and pricing story now, not a risk event.

#18. AURA — Aura Biosciences Inc. [Oncology / Bladder]

Price: $7.01 | Cap: $725M | Cash: ~$373M | RSI: 50 | Momentum: -9.4%
Belzupacap sarotalocan (AU-011) — Phase 1b/2 data in non-muscle invasive bladder cancer (Aug 2026 (Est.))
FDA Status: FTD
BSI: 5.77/10

The Intel: AU-011 is a virus-like drug conjugate — synthetic nanoparticles shaped to mimic a virus so they bind tumour cells selectively, carrying a photosensitiser that is then activated by light to generate cell-killing reactive oxygen species, with a secondary immune-stimulating effect. Aura's established work is in ocular melanoma; bladder is the expansion. Non-muscle invasive bladder cancer is defended by BCG immunotherapy and, more recently, Keytruda and nogapendekin alfa in BCG-unresponsive disease, so the competitive bar has risen sharply in two years. With 37 months of runway there is no financing pressure, but this is early data in a new indication for the platform — read it for signal, not for value.

#19. STRO — Sutro Biopharma Inc. [Oncology / ADC]

Price: $24.17 | Cap: $401M | Cash: ~$254M | RSI: 33 | Momentum: -20.6%
STRO-004 — Phase 1 initial data in solid tumors (Aug 2026 (Est.))
BSI: 5.73/10

The Intel: Down 21% on the month with a comfortable balance sheet and a low float, Sutro brings its next antibody-drug conjugate to a first clinical look. STRO-004 targets tissue factor, and the differentiator is manufacturing rather than biology — Sutro's cell-free synthesis platform allows site-specific attachment of the payload, which in principle yields a more stable, more uniform conjugate than conventional methods. That matters because tissue factor is already occupied territory: Pfizer's Tivdak is approved and several next-generation programs are in flight. First-cohort dose-escalation data with limited precedent behind it — a safety and early-activity signal, not a differentiating efficacy event.

#20. CABA — Cabaletta Bio Inc. [Autoimmune / Cell Therapy]

Price: $2.68 | Cap: $437M | Cash: ~$208M | RSI: 46 | Momentum: -16.0%
Resecabtagene autoleucel (rese-cel, RESET-MG) — Phase 1/2 interim update in generalized myasthenia gravis (Aug 2026 (Est.))
BSI: 5.72/10

The Intel: Cabaletta is pushing CD19 CAR-T — engineered T cells that eliminate antibody-producing B cells — out of oncology and into autoimmune disease, using a fully human, 4-1BB-costimulated construct. The premise is a one-time immune reset instead of chronic therapy in generalized myasthenia gravis, where antibodies attack the nerve-muscle junction and cause disabling weakness. The problem is that gMG is now well served by far less invasive options — FcRn inhibitors like efgartigimod (Vyvgart) and complement blockers — so a therapy requiring lymphodepleting conditioning carries a risk/benefit burden those drugs do not. April data at AAN was encouraging but early. Watch depth and durability of remission; anything less than a lasting drug-free response does not justify the procedure.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change. Where a company's reported cash conflicted with its filings, the figure shown reflects the value from the most recent 10-Q or press release, and the discrepancy is noted in the entry.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.3 | Generated: 2026-08-03T10:20:06